Fredag 6 December | 22:11:44 Europe / Stockholm

Kalender

Tid*
2025-06-03 07:00 Bokslutskommuniké 2025
2025-03-03 07:00 Kvartalsrapport 2025-Q3
2024-12-04 - Kvartalsrapport 2025-Q2
2024-09-26 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2024-09-25 - Årsstämma
2024-08-29 - Kvartalsrapport 2025-Q1
2024-05-30 - Bokslutskommuniké 2024
2024-02-29 - Kvartalsrapport 2024-Q3
2023-12-04 - Kvartalsrapport 2024-Q2
2023-10-04 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2023-09-27 - Årsstämma
2023-08-31 - Kvartalsrapport 2024-Q1
2023-06-08 - Bokslutskommuniké 2023
2023-03-01 - Kvartalsrapport 2023-Q3
2022-12-01 - Kvartalsrapport 2023-Q2
2022-10-03 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2022-09-28 - Årsstämma
2022-08-31 - Kvartalsrapport 2023-Q1
2022-06-10 - Bokslutskommuniké 2022
2022-03-02 - Kvartalsrapport 2022-Q3
2021-12-02 - Kvartalsrapport 2022-Q2
2021-09-09 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2021-09-02 - Kvartalsrapport 2022-Q1
2021-05-31 - Bokslutskommuniké 2021
2021-03-03 - Kvartalsrapport 2021-Q3
2020-12-02 - Kvartalsrapport 2021-Q2
2020-09-30 - Årsstämma
2020-09-09 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2020-08-24 - Kvartalsrapport 2021-Q1
2020-06-08 - Bokslutskommuniké 2020
2020-04-20 - Extra Bolagsstämma 2020
2020-03-02 - Kvartalsrapport 2020-Q3
2019-12-02 - Kvartalsrapport 2020-Q2
2019-09-30 - Årsstämma
2019-09-25 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2019-09-02 - Kvartalsrapport 2020-Q1
2019-06-10 - Bokslutskommuniké 2019
2019-03-04 - Kvartalsrapport 2019-Q3
2018-12-17 - Kvartalsrapport 2019-Q2
2018-09-25 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2018-09-24 - Årsstämma
2018-09-24 - Kvartalsrapport 2019-Q1
2018-06-25 - Bokslutskommuniké 2018
2018-03-26 - Kvartalsrapport 2018-Q3
2017-12-18 - Kvartalsrapport 2018-Q2
2017-09-25 - Årsstämma
2017-09-25 - Kvartalsrapport 2018-Q1
2017-06-30 - Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Integrum är verksamt inom medicinteknik. Idag utvecklar bolaget system för skelettförankrade proteser baserat på det framtagna OPRA-implantatsystemet, som senare vidaresäljs till sjukhus världen över. Implantatet sätts på patientens ben med hjälp utav titanskruvar och antas förbättra livet för en stor del patienter med amputation. Bolaget grundades 1998 och har sitt huvudkontor i Mölndal.
2023-06-08 08:00:00

Mölndal, Sweden, June 8, 2023 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announced that Shirley Ryan AbilityLab - a top-ranked physical medicine and rehabilitation hospital based in Chicago, US - has received a five-year clinical research grant totaling USD 8.7 million from the National Institutes of Health (NIH). The grant will be used to fund two clinical trials evaluating the function of Integrum's e-OPRA[TM] Implant System. It is anticipated that Integrum will receive  up to USD 1.3 million during the program to support the study activities.

Shirley Ryan AbilityLab is a global leader in the field of bionics - the study of mechanical systems that mimic parts of living organisms. The NIH grant will be used to fund the first clinical program in the world combining osseointegration, targeted muscle reinnervation (TMR) and pattern-recognition control, using implanted electromyographic (EMG) sensors. Through the combination of these technologies, individuals who have experienced upper limb loss may recover lower arm functionality and sensation of touch.

The clinical trials aim to evaluate the comfort and function of the implanted electrodes of Integrum's e-OPRA[TM ]Implant System in an in-home environment, as well as its functionality in providing sensory feedback to the central nervous system. Integrum will be supplying e-OPRA implant systems to Shirley Ryan AbilityLab, and surgeons at Northwestern Medicine will implant the devices and perform TMR surgery in eight study participants.

"The NIH grant awarded to Shirley Ryan AbilityLab equates to significant recognition from one of the world's most prestigious research institutions, underscoring the potential of Integrum's e-OPRA Implant System. We look forward to contributing to this important initiative that aims to validate our groundbreaking technology and hope to take it yet another step further toward potential marketing approval," comments Rickard Brånemark, CEO of Integrum.

The grant is funded through the NIH's UG3 and UH3 mechanisms, which are specifically targeted at translating groundbreaking neural technologies for patients.

This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 08-06-2023 08:00 CET.